Clearmind announces patent publication for cocaine addiction treatment by KIPO

Clearmind Medicine (CMND) announced the publication of a patent by the Korean Intellectual Property Office, South Korea’s official patent and intellectual property authority. The patent covers the company’s combination therapy of MEAI and N-Acylethanolamines for the treatment of cocaine addiction. The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center at Bar-Ilan University in Israel. These studies build upon earlier experiments in which animals treated with MEAI exhibited a significant reduction in cocaine-induced cravings. Further research was conducted in rats to assess whether MEAI’s effects on drug-seeking behavior extended to natural rewards, given that reward-based reinforcement is a fundamental survival mechanism across species. The study produced positive results, demonstrating that while MEAI reduced cocaine-seeking behavior, it did not impair the rats’ response to natural rewards such as sucrose. This finding suggests that MEAI’s impact on drug cravings is not tied to the general reward system but is specifically targeted at drug-related compulsions. This research has led to multiple patent applications in the U.S. and other global jurisdictions and is part of Clearmind’s ongoing collaboration with SciSparc (SPRC).